Cargando…
Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go
The aim of therapeutic dendritic cell (DC) vaccines in cancer immunotherapy is to activate cytotoxic T cells to recognize and attack the tumor. T cell activation requires the interaction of the T cell receptor with a cognate major-histocompatibility complex-peptide complex. Although initiated by ant...
Autores principales: | Vasaturo, Angela, Di Blasio, Stefania, Peeters, Deborah G. A., de Koning, Coco C. H., de Vries, Jolanda M., Figdor, Carl G., Hato, Stanleyson V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3847559/ https://www.ncbi.nlm.nih.gov/pubmed/24348481 http://dx.doi.org/10.3389/fimmu.2013.00417 |
Ejemplares similares
-
STAT Family Protein Expression and Phosphorylation State during moDC Development Is Altered by Platinum-Based Chemotherapeutics
por: de Haas, Nienke, et al.
Publicado: (2019) -
The chemotherapeutic drug oxaliplatin differentially affects blood DC function dependent on environmental cues
por: Tel, Jurjen, et al.
Publicado: (2011) -
Improving cancer immunotherapy by targeting the STATe of MDSCs
por: de Haas, Nienke, et al.
Publicado: (2016) -
Preclinical exploration of combining plasmacytoid and myeloid dendritic cell vaccination with BRAF inhibition
por: Tel, Jurjen, et al.
Publicado: (2016) -
Human CD1c(+) DCs are critical cellular mediators of immune responses induced by immunogenic cell death
por: Di Blasio, Stefania, et al.
Publicado: (2016)